Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

In a report released today, Stacy Ku from TD Cowen maintained a Buy rating on Aurinia Pharmaceuticals, with a price target of $17.00. Ku covers the...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AUPH	$15.35	-1.22%	598.09K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AUPH	$15.35	-1.2%	598.09K
3
4
5
6

AUPH

AUPH

Dividend Overview

Get Aurinia Pharmaceuticals Inc Data in Excel

Get Aurinia Pharmaceuticals Inc Data in Excel